Ranolazine (dihydrochloride)

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

Product Specifications

CAS Number

[95635-56-6]

Product Name Alternative

CVT 303 (dihydrochloride) ; RS 43285

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Autophagy; Calcium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/ranolazine-dihydrochloride.html

Purity

99.99

Solubility

DMSO : ≥ 50 mg/mL|H2O : ≥ 50 mg/mL

Smiles

O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2.[H]Cl.[H]Cl

Molecular Formula

C24H35Cl2N3O4

Molecular Weight

500.46

Precautions

H315, H319

References & Citations

[1]Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[2]Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.|[3]Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

J Invest Dermatol. 2023 Feb;143 (2) :305-316.e5.|Pharmaceutics. 2024 May 29;16 (6) :728.|Theranostics. 2018 Oct 29;8 (19) :5452-5468. |Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378 (1879) :20220163.